MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2024-25)
- Udyam number
- UDYAM-DL-01-0014947
Daikon Pharmaceuticals Private Limited
Daikon Pharmaceuticals Private Limited - trading in Delhi, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹6.49 Cr
▲ 7% YoY
Net profit · FY 2025
₹8.88 Lakh
Net margin 1.4%
EBITDA · FY 2025
₹15.16 Lakh
EBITDA margin 2.3%
Authorised capital
₹10 Lakh
Registered with MCA
Paid-up capital
₹10 Lakh
Issued & subscribed
Open charges
₹49 Lakh
Secured borrowings
Company age
8 yrs
Est. 2018
Directors on board
2
As per MCA filings
About Daikon Pharmaceuticals Private Limited
Data last updated:
Daikon Pharmaceuticals Private Limited is a private limited company based in Delhi, India. It operates in the wholesale trading and distribution segment of the trading and commerce sector. It was incorporated on 08 March 2018 and has been in existence for over 8 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U74994DL2018PTC330537. Its GSTIN is 10AAGCD5814J1ZX (Bihar).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Amrit Kaushal (Managing Director) and Menka Kumari.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at E – 16/1530 Plot No – 68 Bapa Nagar Arya Samaj Road Karol Bagh, Delhi, India – 110005.
As per the financials filed for FY 2025, the company reported a revenue of ₹6.49 Cr, a growth of 7% compared to the previous year. For the same year it recorded a net profit of ₹8.88 Lakh (net margin 1.4%) and EBITDA of ₹15.16 Lakh (EBITDA margin 2.3%). Revenue has grown at a compounded annual rate (CAGR) of 17% over three years and 9% over five years.
As per MCA filings, the company has open charges of ₹49 Lakh on record.
Daikon Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-DL-01-0014947).
Company details
CIN U74994DL2018PTC330537
Registration Number 330537
Incorporation Date 08 March 2018
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
MSME Classification Micro
Udyam Registration UDYAM-DL-01-0014947
Recognitions & Rankings of Daikon Pharmaceuticals
Contact details
Daikon Pharmaceuticals Private Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressE – 16/1530 Plot No – 68 Bapa Nagar Arya Samaj Road Karol Bagh, Delhi, India – 110005
- IndustryTrading, Wholesale, Other Wholesale
To see the full contact details of Daikon Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Daikon Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of Daikon Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Daikon Pharmaceuticals Private Limited, buy the company report.
Financials of Daikon Pharmaceuticals Private Limited
FY 2025 filings availableDaikon Pharmaceuticals Private Limited reported revenue of ₹6.49 Cr (up 7% YoY) for FY 2025.
Revenue · FY 2025
₹6.49 Cr ▲ 7%
Net profit · FY 2025
₹8.88 Lakh margin 1.4%
EBITDA · FY 2025
₹15.16 Lakh margin 2.3%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 7%
3 years · compounded
▲ 17%
5 years · compounded
▲ 9%
EBITDA CAGR growth
1 year
▲ 35%
3 years · compounded
▲ 41%
5 years · compounded
▲ 51%
Revenue has grown at a compounded annual rate (CAGR) of 9% over five years, including 7% growth in the latest year. EBITDA rose 35% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹15.16 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹8.88 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 2.3% | ||||
| Net Profit Margin | 1.4% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Daikon Pharmaceuticals Private Limited, buy the company report.
Board of directors of Daikon Pharmaceuticals Private Limited
Daikon Pharmaceuticals has 2 directors on record. No former directors are listed.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Amrit Kaushal Also directs: Concur Pharmaceuticals Private Limited | Managing Director | 08 Mar 2018 | 8 Years 7 Months | Current |
| Menka Kumari | Director | 08 Mar 2018 | 8 Years 7 Months | Current |
Peer comparison
Daikon Pharmaceuticals Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Grahams Pharmaceuticals Private Limited | ₹6.5 Cr (FY 2024) | -12.0% | Kochi, Kerala, India | |||
| Alleviare Life Sciences Private Limited | ₹6.49 Cr (FY 2025) | 2.0% | New Delhi, Delhi, India | |||
| Rawia International Healthcare Private Limited | ₹6.49 Cr (FY 2025) | -24.0% | Mumbai, Maharashtra, India | |||
| Daikon Pharmaceuticals Private Limitedthis company | ₹6.49 Cr (FY 2025) | ₹8.88 Lakh | 1.4% | 7.0% | Delhi, India | |
| Bravo Pharmaceuticals Private Limited | ₹6.47 Cr (FY 2024) | 750.0% | New Delhi, Delhi, India |
To see the full peer comparison of Daikon Pharmaceuticals Private Limited, buy the company report.
Auditor
Daikon Pharmaceuticals Private Limited is audited by ADISH JAIN for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| ADISH JAIN | FY 2024 | 515436 |
Shareholding
The shareholding of Daikon Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Daikon Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹49 Lakh
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 04 Aug 2024 | 100972929 | Others | ₹49 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Daikon Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Daikon Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Daikon Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 10AAGCD5814J1ZX | Bihar | Active | 11 May 2018 |
To see the full GST registrations and return filing status of Daikon Pharmaceuticals Private Limited, buy the company report.
Recent activity
Daikon Pharmaceuticals Private Limited has 2 board changes on record since 2018: 2 appointments. The latest: Amrit Kaushal was appointed as Managing Director on 08 Mar 2018.
AGM
Daikon Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Daikon Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi.
Charges
A charge with Others amounted to Rs. 49.00 Lakh with Charge ID 100972929 was registered on 04 Aug 2024.
Appointed
Amrit Kaushal was appointed as Managing Director.
Appointed
Menka Kumari was appointed as Director.
Incorporation
08 Mar 2018
Daikon Pharmaceuticals Private Limited was registered on 08 Mar 2018 with Roc Delhi & aged 8 years 7 months as per MCA records.
Frequently asked questions
Daikon Pharmaceuticals is an active private limited company based in Delhi, India. The company works in wholesale, within the trading industry. It was incorporated on 08 March 2018 (8+ years old) and is registered under CIN U74994DL2018PTC330537.
Daikon Pharmaceuticals has 2 current directors:
- Amrit Kaushal - Managing Director
- Menka Kumari - Director
The latest financial statements of Daikon Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from FY 2018 are in the company report.
The GSTIN of Daikon Pharmaceuticals is 10AAGCD5814J1ZX, registered in Bihar.
The CIN (Corporate Identification Number) of Daikon Pharmaceuticals is U74994DL2018PTC330537. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Daikon Pharmaceuticals was incorporated on 08 March 2018, making it 8+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Daikon Pharmaceuticals by revenue are Grahams Pharmaceuticals Private Limited, Alleviare Life Sciences Private Limited, Rawia International Healthcare Private Limited, Bravo Pharmaceuticals Private Limited, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading).
Amrit Kaushal was appointed as Managing Director on 08 Mar 2018. Menka Kumari was appointed as Director on 08 Mar 2018.
Yes, Daikon Pharmaceuticals is registered as a micro enterprise under Udyam registration (number: UDYAM-DL-01-0014947).
The registered office of Daikon Pharmaceuticals is at E – 161530 Plot No – 68 Bapa Nagar Arya Samaj Road Karol Bagh, Delhi, India – 110005.
Daikon Pharmaceuticals operates in the trading industry, in the wholesale segment.